StockData
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. (TNYA) stock

TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$0.32−0.01 (-3.24%)

Close on Nov 17, 2026Market cap $72.38MP/E –Yield –

Tenaya Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Tenaya Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $61.61M, down 20.5% year over year. For fiscal 2025 it was $68.61M, down 20.9% from the year before. The highest annual figure on record is $98.04M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$68.61M-20.9%
FY2024Dec 31, 2024$86.74M-11.5%
FY2023Dec 31, 2023$98.04M+3.7%
FY2022Dec 31, 2022$94.54M+73.8%
FY2021Dec 31, 2021$54.39M+74.9%
FY2020Dec 31, 2020$31.10M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.60M-4.4%
Q1 FY2026Mar 31, 2026$14.84M-29.6%
Q4 FY2025Dec 31, 2025$14.80M-20.8%
Q3 FY2025Sep 30, 2025$15.36M-24.5%
Q2 FY2025Jun 30, 2025$17.37M-23.3%
Q1 FY2025Mar 31, 2025$21.08M-15.9%
Q4 FY2024Dec 31, 2024$18.69M-18.3%
Q3 FY2024Sep 30, 2024$20.35M-11.9%
Q2 FY2024Jun 30, 2024$22.65M-14.5%
Q1 FY2024Mar 31, 2024$25.06M-2.1%
Q4 FY2023Dec 31, 2023$22.87M-11.2%
Q3 FY2023Sep 30, 2023$23.09M-2.8%
Q2 FY2023Jun 30, 2023$26.48M+26.8%
Q1 FY2023Mar 31, 2023$25.61M+6.0%
Q4 FY2022Dec 31, 2022$25.75M+22.9%
Q3 FY2022Sep 30, 2022$23.76M+83.5%
Q2 FY2022Jun 30, 2022$20.88M+91.4%
Q1 FY2022Mar 31, 2022$24.16M+151.9%
Q4 FY2021Dec 31, 2021$20.95M+150.5%
Q3 FY2021Sep 30, 2021$12.94M+52.6%
Q2 FY2021Jun 30, 2021$10.91M+56.7%
Q1 FY2021Mar 31, 2021$9.59M–
Q4 FY2020Dec 31, 2020$8.36M–
Q3 FY2020Sep 30, 2020$8.48M–
Q2 FY2020Jun 30, 2020$6.96M–

More Tenaya Therapeutics figures

See a number that looks wrong?